Advocacy to Increase Funding for the National Institutes of Health (NIH) is a top priority for Endocrine Society, and our advocacy has led to significant funding increases for the last seven years despite threats to cut government funding. Our goal is to protect NIH from funding cuts and to ensure that all NIH Institutes receive significant funding increases as a proportionate share of a total increase. We also advocate for special attention to early career scientists and to reduce administrative burdens on scientists. In addition, we raise the visibility of endocrine-related research and researchers.
The Latest
- On March 23, President Biden signed off on the final six-bill appropriations package, finalizing the Fiscal Year (FY) 2024 process. Thanks to Endocrine Society advocacy, the legislation protects funding for the National Institutes of Health (NIH) and includes some targeted increases in funding for several Institutes and Centers. The bill also maintains funding for the Advanced Research Projects Agency for Health (ARPA-H) at $1.5 billion and protects funding for the CDC’s Chronic Care Center, providing over $156 million for diabetes initiatives such as the Diabetes Prevention Program, and over $58 million in funding for the Division of Nutrition, Physical Activity, and Obesity. We sincerely appreciate all our members who took action to ensure that NIH was protected from damaging cuts. Thank you for your advocacy!
- Looking ahead to FYH 2025, beginning October 1, 2024, the Society is advocating for an increase for NIH. Please visit our online advocacy campaign and be on the lookout for additional information about advocacy opportunities.
- Testimony: The Endocrine Society provides annual testimony to the Appropriations Committee recommending funding levels for NIH. In 2023, we highlighted the dangers posed by proposed broad cuts to public health programs, including biomedical research.
- Advanced Research Projects Agency for Health (ARPA-H): The Endocrine Society was invited to present at two different listening sessions by the Biden Administration and discuss how the new agency could benefit endocrine-related science. The Society also urged policy makers to ensure funding for ARPA-H would supplement, not supplant, funding for NIH. Endocrine Society Past President Carol Wysham, MD and President Ursula Kaiser, MD represented the Society at discussions about the creation of ARPA-H.
Read more about the Society's advocacy related to research funding.
